{"preliminary_commentary":{"by_channel":{"x_thread":14,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05820633\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PCS-XI","nct_id":"NCT05820633","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pcs-xi-nct05820633. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PCS-XI","arms":[{"description":"5 radiation treatments (5 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given every other day over 2 weeks for a total of 25 Gy.","label":"ultra hypo fractionation radiation therapy (UHF)","type":"EXPERIMENTAL"},{"description":"20-25 radiation treatments (range: 1,8 to 2,15 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given in 20-25 working day treatments over 4-5 weeks for a total of 43 Gy to 46 Gy.","label":"standard of care fractionation (SOC)","type":"ACTIVE_COMPARATOR"}],"collaborators":["TerSera Therapeutics LLC"],"completion_date":{"date":"2035-12","type":"ESTIMATED"},"conditions":["Prostate Cancer","Node; Prostate","Radiotherapy Side Effect"],"enrollment":{"count":500,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)","otherNames":[],"type":"RADIATION"},{"name":"Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite\" (EPIC-26):","otherNames":[],"type":"RADIATION"},{"name":"Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)","otherNames":[],"type":"RADIATION"},{"name":"Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)","otherNames":[],"type":"RADIATION"},{"name":"Report and compare the biochemical disease free survival (bDFS)","otherNames":[],"type":"RADIATION"},{"name":"Report and compare the disease free survival (DFS)","otherNames":[],"type":"RADIATION"},{"name":"Report and compare the metastase free survival (MFS)","otherNames":[],"type":"RADIATION"},{"name":"Report and compare the overall survival (OS)","otherNames":[],"type":"RADIATION"}],"last_update":"2025-09-12","lead_sponsor":"CHU de Quebec-Universite Laval","official_title":"Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial. (PCS-XI)","overall_status":"SUSPENDED","phases":["NA"],"primary_completion_date":{"date":"2026-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Non-inferiority analysis of early change in genito-urinary (GU) toxicities induced.","timeFrame":"Every 3 months for 1 year."},{"measure":"Non-inferiority analysis of early change in reported Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire.","timeFrame":"Every 3 months for 1 year."},{"measure":"Non-inferiority analysis of late change in genito-urinary (GU) toxicities induced.","timeFrame":"Every 6 months up to 36 months, then annually up to 10 years."},{"measure":"Non-inferiority analysis of late change in reported Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire.","timeFrame":"Every 6 months up to 36 months, then annually up to 10 years."},{"measure":"Non-inferiority analysis of early change in sexual health.","timeFrame":"Every 3 months for 1 year."},{"measure":"Non-inferiority analysis of late change in sexual health.","timeFrame":"Every 6 months up to 36 months, then annually up to 10 years."},{"measure":"Non-inferiority analysis of early change in toxicities reporte via the Common Terminology Criteria for Adverse Events (CTCAE).","timeFrame":"Every 3 months for 1 year."},{"measure":"Non-inferiority analysis of late change in toxicities reporte via the Common Terminology Criteria for Adverse Events (CTCAE).","timeFrame":"Every 6 months up to 36 months, then annually up to 10 years."}],"references":[{"citation":"Huynh-Le MP, Myklebust TA, Feng CH, Karunamuni R, Johannesen TB, Dale AM, Andreassen OA, Seibert TM. Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study. Cancer. 2020 Apr 15;126(8):1691-1699. doi: 10.1002/cncr.32702. Epub 2020 Jan 3.","pmid":"31899813","type":"BACKGROUND"},{"citation":"Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002 Apr;167(4):1681-6.","pmid":"11912387","type":"BACKGROUND"},{"citation":"Greenberger BA, Zaorsky NG, Den RB. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2020 Mar 15;6(2):404-418. doi: 10.1016/j.euf.2019.11.007. Epub 2019 Dec 5.","pmid":"31813810","type":"BACKGROUND"},{"citation":"Yin M, Zhao J, Monk P, Martin D, Folefac E, Joshi M, Jin N, Mortazavi A, Verschraegen C, Clinton S. Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer. Cancer Med. 2020 Jan;9(1):27-34. doi: 10.1002/cam4.2605. Epub 2019 Nov 7.","pmid":"31697452","type":"BACKGROUND"},{"citation":"Tharmalingam H, Tsang Y, Choudhury A, Alonzi R, Wylie J, Ahmed I, Henry A, Heath C, Hoskin PJ. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume. Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):525-533. doi: 10.1016/j.ijrobp.2019.09.044. Epub 2019 Oct 11.","pmid":"31610249","type":"BACKGROUND"},{"citation":"Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C, Chung HT, Deabreu A, Mamedov A, Zhang L, Sankreacha R, Vigneault E, Springer C. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol. 2011 Sep;100(3):463-7. doi: 10.1016/j.radonc.2011.08.022. Epub 2011 Sep 14.","pmid":"21924511","type":"BACKGROUND"},{"citation":"Hill RP, Rodemann HP, Hendry JH, Roberts SA, Anscher MS. Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):353-65. doi: 10.1016/s0360-3016(00)01484-x.","pmid":"11173128","type":"BACKGROUND"},{"citation":"Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys. 1985 Jan;11(1):87-96. doi: 10.1016/0360-3016(85)90366-9.","pmid":"3881377","type":"BACKGROUND"},{"citation":"McCammon R, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):413-20. doi: 10.1016/j.ijrobp.2008.10.050. Epub 2009 Apr 11.","pmid":"19362783","type":"BACKGROUND"},{"citation":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Bjornlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellen E, Franzen L, Nilsson P. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18.","pmid":"31227373","type":"BACKGROUND"},{"citation":"Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J, Strigari L. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):11-8. doi: 10.1016/j.ijrobp.2009.07.1691. Epub 2010 Jan 4.","pmid":"20047800","type":"BACKGROUND"},{"citation":"D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289.","pmid":"18212313","type":"BACKGROUND"},{"citation":"Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001 Dec;58(6):843-8. doi: 10.1016/s0090-4295(01)01441-8.","pmid":"11744442","type":"BACKGROUND"},{"citation":"Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):174-185. doi: 10.1016/j.ijrobp.2020.08.034. Epub 2020 Aug 27.","pmid":"32861817","type":"BACKGROUND"},{"citation":"Gregoire JP, Moisan J, Labrecque M, Cusan L, Diamond P. [Validation of a French adaptation of the international prostatic symptom score]. Prog Urol. 1996 Apr;6(2):240-9. French.","pmid":"8777417","type":"BACKGROUND"}],"start_date":{"date":"2022-09-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.","url":"https://clinicaltrials.gov/study/NCT05820633"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pcs-xi-nct05820633"}